Advertisement
Logo
Search for

Volume 19, Issue 3, Pages 159-164 (April 2010)


View previous. 6 of 15 View next.

Treatment and long term outcome in West syndrome: The clinical reality. A multicentre follow up study

Lieven LagaeaCorresponding Author Informationemail address, Helène Verhelstb, Berten Ceulemansc, Linda De Meirleird, Marie-Cécile Nassognee, Valerie De Borchgravef, Marc D’Hoogheg, Martine Foulonh, Patrick Van Bogaerti

Received 16 July 2009; received in revised form 12 December 2009; accepted 15 January 2010. published online 11 February 2010.

Abstract 

We systematically reviewed the files of 51 infants presenting with infantile spasms and hypsarrhythmia in order to study the initial treatment strategies and the long term outcome. 80% of the infants were classified as symptomatic. In the nine participating centres, different treatment protocols were used, but the large majority of the children received vigabatrin as first line treatment. Second line options included hormonal treatment, topiramate and valproate. The time to reach cessation of infantile spasms was significantly shorter in the cryptogenic group than in the symptomatic group (50% at 13 days versus 66 days respectively) and was irrespective of the treatment used. The late follow up data (>2 years) showed that 60% of the children had epilepsy and that 75% of the children had a delay in their psychomotor development. Again, outcome in the cryptogenic group was better than in the symptomatic group, but also in the cryptogenic group, 50% of the children had a clear developmental delay, even if spasms were controlled early in the course of the disease. Our retrospective study illustrates that not only the underlying brain dysfunction is the major determinant for later outcome in infantile spasms (symptomatic group) but also even a short period of infantile spasms can be responsible for later developmental delay (cryptogenic group).

a University Hospitals KULeuven, Department of Pediatric Neurology, Herestraat 49, 3000 Leuven, Belgium

b Ghent University Hospital, Department of Pediatric Neurology, De Pintelaan 185, 9000 Ghent, Belgium

c University Hospitals Antwerp, Department of Pediatric Neurology, Wilrijkstraat 10, 2650 Edegem, Belgium

d University Hospitals VUBrussels, Department of Pediatric Neurology, Laarbeeklaan 101, 1090 Jette, Belgium

e Clinique Universitaire St. Luc, Department of Neurology, Avenue Hippocrate 10, 1200 Woluwe-St-Lambert, Belgium

f Centre Neurologique William Lennox, Allée de Clerlande 6, 1340 Ottignies, Belgium

g Algemeen Ziekenhuis Sint Jan Brugge, Department of Neurology and Child Neurology, Ruddershove 10, 8000 Brugge, Belgium

h CHU Charleroi, Department of Psychiatry, Boulevard Paul Janson 92, 6000 Charleroi, Belgium

i AZ Erasmus, Lenniksebaan 808, 1070 Anderlecht, Belgium

Corresponding Author InformationCorresponding author. Tel.: +32 16 34 38 45; fax: +32 16 34 38 42.

PII: S1059-1311(10)00009-9

doi:10.1016/j.seizure.2010.01.008


View previous. 6 of 15 View next.